- Acquired by Highbridge Capital Management, Mar 2024
- Raised $30M funding round, May 2024
- Raised $25M funding round, Sep 2022
About
Gamida Cell is pioneering a diverse approach to cellular therapy that utilizes nicotinamide (NAM) to expand multiple cell types — including stem cells and natural killer (NK) cells — while maintaining their original phenotype and potency. When applied to umbilical cord blood–derived cells in the production of our investigational omidubicel product for allogeneic stem cell transplant, NAM-enabled cells have improved clinical measures such as engraftment time and infection rate, potentially leading to better outcomes for patients.
Gamida Cell has developed a reliable, scalable and GMP-compliant culture method for NAM expansion that yields highly functional NK cells. These cells have demonstrated ability to kill cancerous cells in both animal models and clinical trials, and are being developed in both unmodified and genetically engineered forms.
The company received FDA approval for Omisirge (omidubicel-onlv), an allogenic cell therapy to reduce the risk of infection in blood cancer patients.
Funding history · 13 rounds · $416.2M total
Q&A
- What is Gamida Cell's primary focus?
- Gamida Cell is focused on pioneering cellular therapy that uses nicotinamide (NAM) to expand various cell types, including stem cells and natural killer (NK) cells, for applications in allogeneic stem cell transplant and cancer treatment.
- When was Gamida Cell acquired and by whom?
- Gamida Cell was acquired by Highbridge Capital Management in March 2024.
- What significant regulatory approval has Gamida Cell received?
- Gamida Cell received FDA approval for Omisirge (omidubicel-onlv), an allogeneic cell therapy designed to reduce the risk of infection in blood cancer patients.
- How many employees does Gamida Cell have?
- Gamida Cell has 51–200 employees.
- What was Gamida Cell's most recent funding round?
- In May 2024, Gamida Cell raised $30,000,000 from Highbridge Capital Management.
- What is the total amount of funding Gamida Cell has raised to date?
- Gamida Cell has raised a total of $416,223,389 in funding.
- Where is Gamida Cell headquartered?
- Gamida Cell is headquartered in Kiryat Gat, Israel, with an additional office in Boston, MA, USA.
- What is Gamida Cell's current product stage?
- Gamida Cell's product is in the clinical trial stage.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | gamida-cell.com |
|---|---|
| linkedin.com/company/8310772 | |
| facebook.com/GamidaCellLtd | |
| instagram.com/gamidacelltx/?hl=en | |
| Wikidata | wikidata.org/wiki/Q30269027 |
Identifiers & details
| Founded | 1998-2 |
|---|---|
| Employees (exact) | 93 |
| Offices | Boston |
| Market cap | $4.3M |
| Status reason | Acquired by Highbridge Capital Management on Mar 2024 |
| Wikidata QID | Q30269027 |
Acquisitions & public offerings
Acquired by Highbridge Capital Management 2024-03
Radar intelligence
Patents
| EPO | 42 |
|---|
Web history (Wayback)
| Domain | gamida-cell.com |
|---|
Wikidata
| QID | Q30269027 |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|